Yutaka Niihara - 26 Sep 2022 Form 4 Insider Report for Emmaus Life Sciences, Inc. (EMMA)

Role
Chairman and CEO, Director, 10%+ Owner
Signature
Yutaka Niihara, M.D., M.P.H.
Issuer symbol
EMMA
Transactions as of
26 Sep 2022
Net transactions value
+$20,370
Form type
4
Filing time
12 Oct 2022, 13:04:08 UTC
Previous filing
02 Jun 2022
Next filing
13 Oct 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction EMMA Common stock, $0.001 par value Purchase $1,200 +6,000 +0.05% $0.2000 11,339,857 26 Sep 2022 Direct F1
transaction EMMA Common stock, $0.001 par value Purchase $1,000 +5,000 +0.04% $0.2000 11,344,857 27 Sep 2022 Direct F1
transaction EMMA Common stock, $0.001 par value Purchase $2,000 +10,000 +0.09% $0.2000 11,354,857 03 Oct 2022 Direct F1
transaction EMMA Common stock, $0.001 par value Purchase $800 +5,000 +0.04% $0.1600 11,359,857 04 Oct 2022 Direct F1
transaction EMMA Common stock, $0.001 par value Purchase $1,500 +10,000 +0.09% $0.1500 11,369,857 05 Oct 2022 Direct F1
transaction EMMA Common stock, $0.001 par value Purchase $750 +5,000 +0.04% $0.1500 11,374,857 06 Oct 2022 Direct F1
transaction EMMA Common stock, $0.001 par value Purchase $520 +4,000 +0.04% $0.1300 11,378,857 07 Oct 2022 Direct F1
transaction EMMA Common stock, $0.001 par value Purchase $900 +10,000 +0.09% $0.0900 11,388,857 10 Oct 2022 Direct F1
transaction EMMA Common stock, $0.001 par value Purchase $11,700 +130,000 +1.1% $0.0900 11,518,857 11 Oct 2022 Direct F1, F2
holding EMMA Common stock, $0.001 par value 92,794 26 Sep 2022 By Hope International Hospice, Inc. F3
holding EMMA Common stock, $0.001 par value 63,000 26 Sep 2022 By Soomi Niihara
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares shown include shares owned jointly with Soomi Niihara, the reporting person's wife.
F2 The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.08 to $0.12, inclusive. The reporting person undertakes to provide to Emmaus Life Sciences, Inc., any security holder of Emmaus Life Sciences, Inc., and the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (2).
F3 Hope International Hospice, Inc. is a California corporation of which Dr. Niihara and his wife are the sole shareholders and directors.